Page 7 - Read Online
P. 7

29         The secondary prevention of hepatitis B virus-associated hepatocellular carcinoma
                            Bo-Bin Hu, Rong-Ming Wang, Jian-Ning Jiang
                            Hepatoma Res 2019;5:29  http://dx.doi.org/10.20517/2394-5079.2019.23


               30         The role of APOBEC3B in the development of hepatocellular carcinoma should be investigated
                            with the consideration of hepatitis B virus evolution
                            Wen-Bin Liu, Guang-Wen Cao
                            Hepatoma Res 2019;5:30  http://dx.doi.org/10.20517/2394-5079.2019.27

               31         No evidence for higher rates of hepatocellular carcinoma after direct-acting antiviral treatment:
                            a meta-analysis
                            Stephanie M. Rutledge, Hui Zheng, Darrick K. Li, Raymond T. Chung
                            Hepatoma Res 2019;5:31  http://dx.doi.org/10.20517/2394-5079.2019.19

               32         Immune checkpoint blockade therapies for HCC: current status and future implications
                            Ritu Shrestha, Kim R. Bridle, Darrell H. G. Crawford, Aparna Jayachandran
                            Hepatoma Res 2019;5:32  http://dx.doi.org/10.20517/2394-5079.2019.24


               33         Comment on “APOBEC3B interaction with PRC2 modulates microenvironment to promote HCC
                            progression”
                            Beiying Dai
                            Hepatoma Res 2019;5:33  http://dx.doi.org/10.20517/2394-5079.2019.26


               34         The use of cell free DNA in the diagnosis of HCC
                            Bubu A. Banini, Arun J. Sanyal
                            Hepatoma Res 2019;5:34  http://dx.doi.org/10.20517/2394-5079.2019.30

               35         Hepatocellular carcinoma in HCV - liver cirrhosis before and after successful DAA treatment
                            Zahari Krastev, Deian Jelev, Donika Krasteva, Jordan Genov, Teodora Komitova
                            Hepatoma Res 2019;5:35  http://dx.doi.org/10.20517/2394-5079.2019.02


               36         Tumor growth rates and recurrence-free survival in chronic viral hepatitis patients with
                            hepatocellular carcinoma
                            Myron J. Tong, Dahlia A. Kaki, Claiborne T. Huynh, Steven S. Raman, David S. Lu
                            Hepatoma Res 2019;5:36  http://dx.doi.org/10.20517/2394-5079.2019.005


               37         Updates in immunotherapy for hepatocellular carcinoma
                            Leonardo G. da Fonseca, Flair José Carrilho
                            Hepatoma Res 2019;5:37  http://dx.doi.org/10.20517/2394-5079.2019.012

               38         Ten-year survival and recurrence of hepatocellular cancer
                            Tomoki Sempokuya, Linda L. Wong
                            Hepatoma Res 2019;5:38  http://dx.doi.org/10.20517/2394-5079.2019.013
   2   3   4   5   6   7   8   9   10   11   12